Trials / Unknown
UnknownNCT05485350
Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Single-arm Clinical Study of Anlotinib Combined With Penpulimab Plus SBRT in Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- Sponsor
- Peking University Third Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will explore the effectiveness and safety of the combination therapy of anlotinib , penpulimab and SBRT in patients with metastatic non-small Cell Lung Cancer (NSCLC)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anlotinib Hydrochloride | 12 mg/d, d1-14, q3w |
| DRUG | penpulimab | 200mg, ivgtt, d1, q3w |
| RADIATION | SBRT | 55-180Gy |
Timeline
- Start date
- 2022-09-12
- Primary completion
- 2023-09-21
- Completion
- 2024-10-15
- First posted
- 2022-08-03
- Last updated
- 2022-08-03
Source: ClinicalTrials.gov record NCT05485350. Inclusion in this directory is not an endorsement.